{
    "id": "54f63f99-bc46-4d32-a518-9b7b20d79943",
    "indications": "xphozah indicated reduce serum phosphorus adults chronic kidney disease ( ckd ) dialysis add-on therapy patients inadequate response phosphate binders intolerant dose phosphate binder therapy .",
    "contraindications": "recommended : 30 mg orally twice daily morning evening meals ( 2.1 ) . manage serum phosphorus levels tolerability adjustments ( 2.1 ) . take prior first last meals day ( 2.2 ) . instruct patients take right hemodialysis session , instead take right next meal following dialysis ( 2.2 ) .",
    "warningsAndPrecautions": "xphozah supplied 10- , 20- , 30-mg oval , biconvex , film-coated tablets supplied white , opaque , high-density polyethylene bottles containing 60 14 tablets silica gel canister ( desiccant ) screw-top polypropylene child-resistant cap lined induction-activated aluminum foil liner : strength color deboss ndc bottle/14 bottle/60 10 mg yellow /t10 73154-110-14 73154-110-60 20 mg brown /t20 73154-120-14 73154-120-60 30 mg red /t30 73154-130-14 73154-130-60",
    "adverseReactions": "xphozah contraindicated patients 6 years age risk diarrhea serious dehydration [ ( 5.1 ) , ( 8.5 ) ] . xphozah contraindicated patients known suspected mechanical gastrointestinal obstruction .",
    "ingredients": [
        {
            "name": "TENAPANOR HYDROCHLORIDE",
            "code": "50605O2ZNS"
        }
    ],
    "organization": "Ardelyx, Inc.",
    "name": [
        {
            "name": "XPHOZAH 10 mg"
        },
        {
            "name": "XPHOZAH 20 mg"
        },
        {
            "name": "XPHOZAH 30 mg"
        }
    ],
    "effectiveTime": "20250404",
    "indications_original": "XPHOZAH is indicated to reduce serum phosphorus in adults with chronic kidney disease (CKD) on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant of any dose of phosphate binder therapy.",
    "contraindications_original": "Recommended dosage: 30 mg orally twice daily before the morning and evening meals ( 2.1 ). Manage serum phosphorus levels and tolerability with dosage adjustments ( 2.1 ). Take just prior to the first and last meals of the day ( 2.2 ). Instruct patients not to take right before a hemodialysis session, and instead take right before the next meal following dialysis ( 2.2 ).",
    "warningsAndPrecautions_original": "XPHOZAH is supplied as 10-, 20-, or 30-mg oval, biconvex, film-coated tablets supplied in white, opaque, high-density polyethylene bottles containing 60 or 14 tablets with a silica gel canister (as the desiccant) and screw-top polypropylene child-resistant cap lined with an induction-activated aluminum foil liner:\n                  \n                     \n                     \n                     \n                     \n                     \n                     \n                        \n                           Strength\n                           Color\n                           Deboss\n                           NDC\n                        \n                        \n                           Bottle/14\n                           Bottle/60\n                        \n                     \n                     \n                        \n                           10 mg\n                           Yellow\n                           \n                              \n                                 /T10\n                           \n                           73154-110-14\n                           73154-110-60\n                        \n                        \n                           20 mg\n                           Brown\n                           \n                              \n                                 /T20\n                           \n                           73154-120-14\n                           73154-120-60\n                        \n                        \n                           30 mg\n                           Red\n                           \n                              \n                                 /T30\n                           \n                           73154-130-14\n                           73154-130-60",
    "adverseReactions_original": "XPHOZAH is contraindicated in patients under 6 years of age because of the risk of diarrhea and serious dehydration [see Warnings and Precautions (5.1), Use in Specific Populations (8.5)].\n                  \n                  XPHOZAH is contraindicated in patients with known or suspected mechanical gastrointestinal obstruction."
}